Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | LDHB | P07195 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LATS1 | O95835 | 2/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CDK4 | P11802 | 2/20 | 0.40 |
| ▸ | CCND1 | P24385 | 2/20 | 0.40 |
| ▸ | LDHA | P00338 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3000655 | 0.84 | AURKA (0.45) | AURKARPS6KB1AURKBLDHBMAPT | |
| SCHEMBL8090080 | 0.70 | GBA1 (0.43) | — | |
| SCHEMBL2998232 | 0.69 | EGFR (0.46) | AURKARPS6KB1MEN1KMT2AEGFR | |
| SCHEMBL913833 | 0.65 | AURKA (0.54) | AURKARPS6KB1AURKBLDHBLDHA | |
| SCHEMBL28096475 | 0.64 | ACP1 (0.59) | MAPTMEN1KMT2A | |
| SCHEMBL25243367 | 0.63 | MAPT (0.67) | MAPTMEN1HTTKMT2ALATS1 | |
| SCHEMBL3265691 | 0.63 | MAPT (0.44) | AURKAAURKBMAPTMEN1KMT2A | |
| SCHEMBL27503639 | 0.62 | EGFR (0.65) | AURKARPS6KB1AURKBEGFRKRAS | |
| SCHEMBL13685106 | 0.61 | NUDT1 (0.47) | AURKARPS6KB1AURKBLDHBLDHA | |
| SCHEMBL4967279 | 0.61 | MEN1 (0.60) | MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0892789-B2 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2009-11-18 | — | — | EP | claimed |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-12-11 | — | — | US | claimed |
| EP-0892789-B1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-02-27 | — | — | EP | claimed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | claimed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | claimed |
| US-7786131-B2 | Anticancer agents; restenosis; atherosclerosis; skin disorders | WARNER-LAMBERT COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| EP-0892789-B2 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20040198752-A1 | ADMINISTERING RETINOIDS WITH EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | ELDER JAMES T (US) | 2004-10-07 | — | — | US | disclosed |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-12-11 | — | — | US | disclosed |
| US-20020169176-A1 | Method for inhibiting retinoid skin damage | ELDER JAMES T (US) | 2002-11-14 | — | — | US | disclosed |
| EP-1230919-A2 | Use of a composition comprising a retinoid and an erb inhibitor in the preparation of a medicament for the treatment of retinoid skin damage | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-0892789-B1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-02-27 | — | — | EP | disclosed |
| US-6344459-B1 | TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS, ENDOMETRIOSIS, AND PSORIASIS | WARNER-LAMBERT COMPANY | 2002-02-05 | — | — | US | disclosed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169176-A1 | Method for inhibiting retinoid skin damage | RARB, EBP, RXRA | AURKA 4045/4885RPS6KB1 912/4885AURKB 3468/4885 |
| US-20040198752-A1 | ADMINISTERING RETINOIDS WITH EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | EGFR, RARB, RXRA | AURKA 3680/4885RPS6KB1 1462/4885AURKB 3633/4885 |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | AURKA 92/4885RPS6KB1 902/4885AURKB 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.